FDA approved lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive GEP-NETs

/0 Comments/in , /by

 

  • FDA approved lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analogue, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults. More Information.
You might also like
Trastuzumab/hyaluronidase-oysk subcutaneous formulation FDA approved for HER2‑overexpressing breast cancer
Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
Dasatinib FDA approved in paediatric patients with chronic phase Ph+ CML
Alectinib FDA approved for ALK-positive metastatic NSCLC
Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
FDA approved brentuximab vedotin plus chemotherapy for untreated stage III or IV classical Hodgkin lymphoma (cHL)
Cabozantinib FDA approved for treatment of patients with advanced renal cell carcinoma
FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA granted regular approval to olaparib in the treatment of (suspected) deleterious...FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk...